237 related articles for article (PubMed ID: 1326212)
1. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II.
Vardi JR; Tadros GH; Zamurovic D; Rafla SD
Acta Obstet Gynecol Scand; 1992 Jul; 71(5):361-7. PubMed ID: 1326212
[TBL] [Abstract][Full Text] [Related]
2. The feasibility of early administration of combination chemotherapy following cytoreductive surgery and second-look operation in patients with stage III ovarian carcinoma: a pilot study.
Vardi JR; Rafla SD; Malhotra C; Tadros G; Charney T; Shebes M; Berkowitz BJ; Kehoe JE; Tancer LM
Gynecol Oncol; 1989 Jul; 34(1):12-5. PubMed ID: 2737518
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
4. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
[TBL] [Abstract][Full Text] [Related]
7. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
8. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Rubin SC; Hoskins WJ; Saigo PE; Chapman D; Hakes TB; Markman M; Reichman B; Almadrones L; Lewis JL
Gynecol Oncol; 1991 Aug; 42(2):137-41. PubMed ID: 1894172
[TBL] [Abstract][Full Text] [Related]
15. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
17. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma.
Högberg T; Kågedal B
Acta Obstet Gynecol Scand; 1990; 69(5):423-9. PubMed ID: 2270768
[TBL] [Abstract][Full Text] [Related]
18. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
20. Second-look laparotomy in the management of patients after radical surgery for ovarian cancer.
Tuxen MK; Lund B; Hansen OP; Hansen M
Ann Oncol; 1993 Feb; 4(2):169-71. PubMed ID: 8448085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
